IPHA
Price:
$1.63
Market Cap:
$126.60M
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 ...[Read more]
Industry
Biotechnology
IPO Date
2019-10-17
Stock Exchange
NASDAQ
Ticker
IPHA
According to Innate Pharma S.A.’s latest financial reports and current stock price. The company's current Enterprise Value is 92.12M. This represents a change of -40.52% compared to the average of 154.87M of the last 4 quarters.
The mean historical Enterprise Value of Innate Pharma S.A. over the last ten years is 182.50M. The current 92.12M Enterprise Value has changed 4.95% with respect to the historical average. Over the past ten years (40 quarters), IPHA's Enterprise Value was at its highest in in the June 2020 quarter at 368.35M. The Enterprise Value was at its lowest in in the June 2015 quarter at 20.38M.
Average
182.50M
Median
176.75M
Minimum
138.25M
Maximum
259.47M
Discovering the peaks and valleys of Innate Pharma S.A. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 77.18%
Maximum Annual Enterprise Value = 259.47M
Minimum Annual Increase = -27.48%
Minimum Annual Enterprise Value = 138.25M
Year | Enterprise Value | Change |
---|---|---|
2023 | 173.09M | -26.48% |
2022 | 235.45M | -9.26% |
2021 | 259.47M | 77.18% |
2020 | 146.45M | -26.80% |
2019 | 200.06M | 23.27% |
2018 | 162.29M | -10.04% |
2017 | 180.41M | 29.88% |
2016 | 138.90M | 0.47% |
2015 | 138.25M | -27.48% |
2014 | 190.64M | 39.47% |
The current Enterprise Value of Innate Pharma S.A. (IPHA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
222.67M
5-year avg
202.90M
10-year avg
182.50M
Innate Pharma S.A.’s Enterprise Value is less than Eliem Therapeutics, Inc. (119.64M), greater than HCW Biologics Inc. (34.47M), greater than Inhibrx Biosciences, Inc. (9.32M), greater than Anebulo Pharmaceuticals, Inc. (36.46M), greater than Pardes Biosciences, Inc. (75.90M), greater than Shattuck Labs, Inc. (6.89M), greater than Champions Oncology, Inc. (66.07M), less than Century Therapeutics, Inc. (104.89M), greater than Addex Therapeutics Ltd (6.58M), greater than Aptorum Group Limited (5.11M), greater than Celyad Oncology SA (1.47M), greater than Dyadic International, Inc. (56.56M), less than Molecular Partners AG (130.63M), greater than MediciNova, Inc. (-41974173594.00), greater than Cyteir Therapeutics, Inc. (-20511738.00),
Company | Enterprise Value | Market cap |
---|---|---|
119.64M | $342.68M | |
34.47M | $29.12M | |
9.32M | $203.82M | |
36.46M | $37.86M | |
75.90M | $135.19M | |
6.89M | $47.98M | |
66.07M | $61.85M | |
104.89M | $102.89M | |
6.58M | $11.57M | |
5.11M | $3.83M | |
1.47M | $14.24M | |
56.56M | $57.11M | |
130.63M | $216.81M | |
-41974173594.00 | $104.47M | |
-20511738.00 | $108.71M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innate Pharma S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innate Pharma S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Innate Pharma S.A.'s Enterprise Value?
What is the highest Enterprise Value for Innate Pharma S.A. (IPHA)?
What is the 3-year average Enterprise Value for Innate Pharma S.A. (IPHA)?
What is the 5-year average Enterprise Value for Innate Pharma S.A. (IPHA)?
How does the current Enterprise Value for Innate Pharma S.A. (IPHA) compare to its historical average?